EAM
RGLS

Exome Asset Management’s Regulus Therapeutics RGLS Stock Holding History

Exome Asset Management’s Portfolio RGLS Stock Details RGLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-402,504
Closed -$1.16M – 69
2024
Q1 		$1.16M Buy
402,504
+224,100
+126% +$365K 0.99% 43
2023
Q4 		$228K Buy
+178,404
New +$238K 0.23% 51

Other funds holding RGLS

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Exome Asset Management's RGLS Position: Q2 2024 in Review

Exome Asset Management sold out of Regulus Therapeutics (RGLS) in Q2 2024, closing a stake of 402,504 shares — an estimated $1.16M sold.

Exome Asset Management first reported a position in RGLS in Q4 2023 and held it in 2 quarters. The position peaked at $1.16M in Q1 2024. 63 funds tracked by Wall St. Rank hold RGLS as of Q2 2024.

  • Exome Asset Management reported no remaining Regulus Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Exome Asset Management sold 402,504 Regulus Therapeutics shares in Q2 2024, an estimated $1.16M.
  • Exome Asset Management first reported a position in Regulus Therapeutics in Q4 2023 and held it in 2 quarters.
  • Exome Asset Management's Regulus Therapeutics position peaked at $1.16M in Q1 2024.
  • 63 funds tracked by Wall St. Rank held Regulus Therapeutics as of Q2 2024.

Based on Exome Asset Management's 13F filing for Q2 2024, filed 14 Aug 2024.